{"id":24882,"date":"2024-07-18T11:30:58","date_gmt":"2024-07-18T09:30:58","guid":{"rendered":"https:\/\/www.izb-online.de\/9th-munich-life-science-pitch-day-im-izb-innovationen-treffen-investoren\/"},"modified":"2024-07-18T11:57:56","modified_gmt":"2024-07-18T09:57:56","slug":"9-munich-life-science-pitch-day-at-the-izb-innovations-meet-investors","status":"publish","type":"post","link":"https:\/\/www.izb-online.de\/en\/9-munich-life-science-pitch-day-at-the-izb-innovations-meet-investors\/","title":{"rendered":"9. Munich Life Science Pitch Day at the IZB: Innovations meet Investors"},"content":{"rendered":"

[vc_row el_class=”gco-magazine-container”][vc_column el_class=”bildspalte”][vc_row_inner][vc_column_inner offset=”vc_col-lg-12 vc_col-md-12″][vc_column_text css=”” el_class=”gco-magazine–title”]<\/p>\n

Life Science Pitch Day at the IZB: Innovations meet Investors<\/h1>\n

[\/vc_column_text][vc_column_text css=”” el_class=”gco-magazine-lead”]Ten start-ups presented their innovative approaches to solving urgent medical issues to over 40 investors at the Munich start-up center.[\/vc_column_text][vc_column_text css=”” el_class=”gco-magazine–post-date”]July, 2024[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_id=”corona-ausblenden”][vc_column_inner][vc_single_image image=”15970″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 Adivo GmbH[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”]Dr. Kathrin Ladetzki-Baehs, Gr\u00fcnderin und Gesch\u00e4ftsf\u00fchrerin von adivo GmbH; Dr. Markus Waldhuber, Gr\u00fcnder und Gesch\u00e4ftsf\u00fchrer adivo GmbH (v.ln.r.)[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine–quote” css=”.vc_custom_1721294564107{margin-top: 33px !important;}” el_id=”corona-ausblenden”][vc_column_inner][vc_column_text]<\/p>\n

\u201eUnser Team entwickelt mit gro\u00dfer Leidenschaft hochinnovative Therapeutika f\u00fcr Haustiere, um die Lebensqualit\u00e4t unserer vierbeinigen Gef\u00e4hrten und ihrer jeweiligen Besitzer deutlich zu verbessern. Wir freuen uns, heute mit einem so erfahrenen Partner bei der Entwicklung von therapeutischen Antik\u00f6rpern f\u00fcr Haustiere zusammenzuarbeiten, um die Innovation in der Tiergesundheit weiter voranzutreiben.\u201c<\/h6>\n

Dr. Kathrin Ladetzki-Baehs
\nGr\u00fcnderin und Gesch\u00e4ftsf\u00fchrerin, adivoG<\/p>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy” css=”.vc_custom_1591795890737{margin-top: 21px !important;}”][vc_column_inner][vc_column_text css=””]Martinsried near Munich, 17 July 2024\u00a0<\/strong>\u2013 On 16 July 2024, the Munich Innovation and Start-up Center for Biotechnology (IZB), in cooperation with High-Tech Gruenderfonds (HTGF), Bayer, Boehringer Ingelheim and MEDICE, hosted the 9th Life Science Pitch Day, which brought together ten biotech start-ups with more than 40 renowned life science investors and decision-makers from the industry. To start with, Christian Gnam, Managing Director of the IZB, gave an insight into current developments at the Munich start-up center and welcomed the attendees as fellow hosts Ingo Kloeckner, Head of Portfolio and Reporting at Leaps by Bayer and Philipp Mueller, Executive Director at Boehringer Ingelheim Venture Fund. Dr. Laura Pedroza, Investment Manager at HTGF, moderated the event.<\/p>\n

The ten selected start-ups presented their innovative approaches for treating a wide range of serious diseases, from bacterial infections to brain tumors. Afterwards, Dr. Daniel Vitt, CEO of IZB alumnus Immunic Therapeutics, gave a keynote speech on the path of a biotech company to a successful IPO.<\/p>\n

\u201cResearch at the highest level was once again presented at this year\u2019s Life Science Pitch Day. This event offers start-ups the ideal opportunity to receive valuable feedback from the venture capital scene in a relaxed atmosphere. I would like to thank our partners for their long-standing support,\u201d commented\u00a0Christian Gnam, Managing Director of the IZB<\/strong>.<\/p>\n

\u201cThe participating start-ups that are turning life science into innovative solutions were able to impress with their pitches,\u201d says\u00a0Philipp M\u00fcller, Boehring Ingelheim Venture Fund<\/strong>.<\/p>\n

\u201cNetworking is of key importance at Life Science Pitch Day. The founders have the opportunity to make valuable new contacts with potential investors, partners and other start-ups,\u201d explains\u00a0Ingo Kloeckner, Leaps by Bayer<\/strong>.<\/p>\n

\u201cWith the Life Science Pitch Day, we have jointly established an excellent event with great added value for all participants. Partnerships are formed here that benefit life science start-ups and investors,\u201d says\u00a0Dr. Laura Pedroza, Investment Manager at HTGF<\/strong>.<\/p>\n

The following project teams presented their groundbreaking research at the 9th Munich Life Science Pitch Day:<\/strong><\/p>\n

    \n
  1. Akribion Therapeutics, Lukas Linnig:<\/strong>\u00a0A new modality of guided cancer cell killing, targeting cancer-specific RNA biomarker expression using easily programmable cytotoxic nucleases with high specificity for wide range of RNA targets<\/li>\n
  2. Citrapeutics, Prof. Frank Pressler:<\/strong>\u00a0First-in-class ACOD1 inhibitors to boost anti-tumor immunity and inhibit cancer cell proliferation for a variety of oncological indications<\/li>\n
  3. immuneAdvice, Dr. Teresa Wagner:<\/strong>\u00a0Visualizes immune cells through non-invasive imaging to guide immunotherapies<\/li>\n
  4. InCephalo Therapeutics, Carlo Bertozzi:<\/strong>\u00a0Develops next-generation therapies for the treatment of brain cancer<\/li>\n
  5. KUPANDO, Johanna Holldack:<\/strong>\u00a0Stimulation of the Oldest Mechanism of Defense: TLRs operate to detect signature molecules that herald infection and cancer by activating the innate immune system<\/li>\n
  6. PREVACTA, Torsten Mummenbrauer:<\/strong>\u00a0A vaccine and therapeutics start-up, combining unique expertise in synthetic (glyco-) chemistry, immunology & clinical infectious diseases<\/li>\n
  7. Quasar Therapeutics, Dr. Arthur Dopler:<\/strong>\u00a0Develops cutting-edge regulators of the complement system to address rare but life-threatening diseases and to solve the problems of current inhibitors in the clinic<\/li>\n
  8. TECregen, Prof. Georg Hollander:<\/strong>\u00a0Immuno-Rejuvenation start-up with the vision to develop transformative, next generation, synthetic ligands to regenerate the thymus<\/li>\n
  9. Teneura, Dr. Niels von Wardenburg:<\/strong>\u00a0Aims to cure neurological autoimmune diseases through T-cell therapies<\/li>\n
  10. TQ Therapeutics, Christin Z\u00fcndorf:<\/strong>\u00a0Develops a novel manufacturing platform for cell therapeutics, that will enable the production of cellular drugs with an integrated, highly automated extracorporeal gene therapy approach<\/li>\n<\/ol>\n

    Press photos for download at:\u00a0www.izb-online.de\/media-library\/images<\/a><\/strong>\u00a0(-> Picture galleries of the Munich Life Science Pitch Day at the IZB)
    \nPress release (Pdf):     Download<\/a><\/strong>[\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”two-columns”][vc_column_inner el_class=”bild-zwei-spalten-links”][vc_single_image image=”24863″ img_size=”full” css=””][vc_column_text css=”” el_class=”gco-magazine-copyright”]\u00a9 IZB\/Dominik Gierke[\/vc_column_text][vc_column_text css=”” el_class=”gco-magazine-picture-discription”]Investors at the Munich Life Science Pitch Day at the Innovation and Start-up Center for Biotechnology (IZB) 2024<\/span>
    \n<\/strong>More than 40 renowned life science investors and industry decision makers met at the 9th Life Science Pitch Day at the IZB.[\/vc_column_text][vc_single_image image=”24867″ img_size=”full” css=””][vc_column_text css=”” el_class=”gco-magazine-copyright”]\u00a9 IZB\/Dominik Gierke[\/vc_column_text][vc_column_text css=”” el_class=”gco-magazine-picture-discription”]Start-up teams at the 9th Munich Life Science Pitch Day 2024:<\/span>
    \n<\/strong>First row (left to right):\u00a0<\/strong>Niels von Wardenburg, Lukas Linnig, Teresa Wagner, Georg Hollander, Carlo Bertozzi
    \nSecond row (left to right):\u00a0<\/strong>Torsten Mummenbrauer, Johanna Holldack, Christin Z\u00fcndorf, Frank Pressler, Arthur Dopler[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy” css=”.vc_custom_1591795890737{margin-top: 21px !important;}”][vc_column_inner][vc_column_text css=””]About the Innovation and Start-up Center for Biotechnology (IZB) in Martinsried near Munich
    \n<\/strong>The F\u00f6rdergesellschaft IZB mbH, founded in 1995, operates the Innovation and Start-up Center for Biotechnology (IZB) with sites in Planegg-Martinsried and Freising-Weihenstephan. The IZB is one of the leading biotechnology centers in Europe. More than 40 biotech and life science companies with over 700 employees are currently located on 26,000 square metres. Here, work is being done on developing drugs for the most serious diseases, such as cancer, Alzheimer\u2019s, and various autoimmune diseases. A key criterion for the success of the IZBs is the physical proximity to cutting-edge research on the Martinsried\/Grosshadern campus and the Weihenstephan campus. The infrastructure measures, such as the Faculty Club G2B (Gateway to Biotech), the hotel CAMPUS AT HOME, the kindergarten Bio Kids as well as the restaurants SEVEN AND MORE and THE BOWL Food Lounge, are also location factors that are highly valued by the founders of the companies. Successful companies that emerged from the IZB include adivo (now Zoetis), Corimmun (today Janssen-Cilag), Crelux (today Wuxi AppTec), Exosome Diagnostics (bought by Bio-Techn), ibidi, Immunic Therapeutics, Medigene, Micromet (today Amgen), MorphoSys (soon Novartis), Octopharma or Rigontec (now MSD) as well as SIRION Biotech (today Perkin Elmer). More information at\u00a0    https:\/\/www.izb-online.de\/en\/<\/a>.<\/p>\n

    Press contact and photo material requests:
    \n<\/strong>Marion K\u00f6hler, Head of Public Relations
    \nF\u00f6rdergesellschaft IZB mbH, Innovations- und Gr\u00fcnderzentrum Biotechnologie
    \nAm Klopferspitz 19
    \nD-82152 Planegg-Martinsried
    \nPhone: +49 (0)89\/55 279 48-17
    \nE-Mail:     koehler@izb-online.de<\/span><\/a><\/p>\n

    About High-Tech Gr\u00fcnderfonds
    \n<\/strong>The seed investor High-Tech Gr\u00fcnderfonds (HTGF) finances tech start-ups with growth potential and has supported more than 750 start-ups since 2005. In its four seed funds, HTGF has about 1.4 billion euros under management. Its team of experienced investment managers and start-up experts support young companies with expertise, entrepreneurial spirit and passion. HTGF\u2019s focus is on high-tech start-ups in the fields of digital tech, industrial tech, life sciences, chemistry and related business areas. To date, external investors have injected about 6 billion euros of capital into the HTGF portfolio via more than 2,000 follow-on financing rounds. In addition, HTGF has already successfully sold shares in more than 180 companies.<\/p>\n

    Fund investors<\/a>\u00a0in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries.\u00a0www.htgf.de\/en<\/a><\/p>\n

    Media contact
    \n<\/strong>High-Tech Gr\u00fcnderfonds Management GmbH
    \nTobias Jacob, Senior Marketing & Communications Manager
    \nT.: +49 228 \u2013 82300 \u2013 121
    \n    t.jacob@htgf.de<\/a>[\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner]\n\n

    \n
    \n